Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · AbCellera Biologics Inc. (ABCL)

AbCellera narrows Q3 2026 net loss to $40.8 million as revenue rises to $10.6 million

Positive Impact 3 of 5 earnings

AbCellera reported third-quarter 2026 results, with total revenue of $10.6 million versus $9.0 million a year earlier and a net loss of $40.8 million, or $(0.13) per share, down from $57.1 million, or $(0.19) per share. The company said it had over $890 million in total available liquidity as of September 30, 2026, including a $200 million share offering that closed August 14, 2026 at $9.75 per share.

Key points

  • Total revenue of $10.6 million in Q3 2026, compared with $9.0 million in Q3 2025
  • Net loss of $40.8 million, or $(0.13) per share, compared with $57.1 million, or $(0.19) per share, in Q3 2025
  • R&D expenses of $43.5 million, down from $55.0 million; SG&A expenses of $13.6 million, down from $25.0 million
  • Positive top-line Phase 2 data for ABCL635 announced in Q3; Phase 1 top-line data for ABCL575 announced after quarter end

The filing

CompanyAbCellera Biologics Inc. (ABCL)
Form8-K, current report
Filed with the SECNov 9, 2026, 4:22 PM ET
Accession number0001703057-26-000058

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 4:46 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.